We Are Trying To Cure Cancer
The biotech market has finally reset after the COVID-era bubble, but new challenges are emerging. From the reality of AI in drug development to the growing competition from China and the critical threat of a “brain drain” in U.S. research, we explore seven key takeaways for investors and founders navigating the future of oncology and life sciences.